Incorporating ACR Guideline Concepts for Rheumatoid Arthritis into Clinical Care

Curriculum:
Managing a Non-Responder to Methotrexate
Credits:
0.75 ANCC Contact Hours 1 CA-BRN Credit(s) 0.75 AMA PRA Category 1 Credit(s)™
Launch Date:
February 26, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Jacqueline Fritz, RN, MSN, CNS

Jacqueline Fritz, RN, MSN, CNS
Medical Advancement Center
Critical Care and Rheumatology Specialist
Cypress, California

Jacqueline Fritz, RN, MSN, CNS, is owner and Coordinator of Education at the Medical Advancement Center in Cypress, CA, where she teaches RN/BSN programs at various facilities. She is also a Critical Care Clinical Nurse Consultant to many acute care facilities in the California area, such as Cigna, Arcadia Methodist, and Doctor's Hospital of Lakewood. She is also an ACLS affiliate and West Coast Regional Director responsible for training and supervising ACLS courses in Los Angeles and Orange County.

Kenneth G. Saag MD, MSc

Kenneth G. Saag MD, MSc
Professor of Medicine, Division of Clinical Immunology and Rheumatology
University of Alabama at Birmingham (UAB) School of Medicine
Birmingham, Alabama

Dr. Saag is a rheumatologist and outcomes researcher with expertise in Musculoskeletal Disorder pharmacoepidemiology and clinical focus in bone health. He is the only rheumatologist on Board of Directors of National Osteoporosis Foundation. He is experienced in population-based investigations, working with large databases, and quality indicator development. Dr. Saag is on the FDA Arthritis Advisory Committee and recently co-chaired the American Medical Association (AMA) Physician Consortium for Performance Improvement on Osteoporosis. He is on the editorial board of Archives of Internal Medicine, Arthritis Care and Research, and Arthritis Research and Therapy. Dr. Saag has previously chaired the Arthritis Foundation Clinical, Therapeutics and Outcomes Study Section, has served on several NIH study sections, IOM Committees, National Committees to develop both arthritis and osteoporosis guidelines, the Musculoskeletal Workgroup of the Cochrane Collaboration, and the National Committee for Quality Assurance workgroup on Arthritis Quality Indicators. 

Vibeke Strand, MD

Vibeke Strand, MD
Clinical Professor, Adjunct
Division of Immunology/Rheumatology
Stanford University School of Medicine
Biopharmaceutical Consultant 
Stanford, California

Dr. Strand serves a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She graduated from Swarthmore College with honors, attended the University of California, San Francisco School of Medicine and returned there to complete her subspecialty Rheumatology Fellowship. She was one of eight in the first Primary Care Internal Medicine Residency at Michigan State University. She has been a clinical rheumatologist for 30 years - in subspecialty practice in San Francisco, as a clinical investigator, as an IRB member and subsequently as the director of clinical research at 3 pharmaceutical and biotech companies. She is a member of the clinical faculty at Stanford University, serving as Clinical Professor, Adjunct, Division of Immunology and Rheumatology since September 2000; Clinical Associate Professor since March 1993, and previously as Assistant and Associate Clinical Professor at University of California San Francisco (1981-1993). Her professional interests include development of outcome measures methodology, and clinical and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases, including rheumatoid arthritis [RA], osteoarthritis [OA], fibromyalgia [FMS], gout, systemic lupus erythematosus [SLE] and systemic sclerosis [SSc].
1. Implement evidence-based guidelines into practice as warranted for the treatment of specific subsets of patients with rheumatoid arthritis (RA)
2. Compare the safety profiles of current biologic DMARDs commonly used for the treatment of RA